1. >
  2. Investors
  3. >
  4. Regulated Information
  5. >
  6. Press Releases – Reg...


Found 303 Results
Page 2 of 31

Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer

Agarwal is Currently Chairwoman of Onxeo’s Board, a Position Held Since June 2021 Company Outlines Development Strategy Plans Including Preparation […]


Onxeo Reports its Full-Year 2021 Financial Results and announces additional financing of €12 million

Cash position of €17.9 million as of December 31, 2021 Additional financing of €12 million subscribed by historical shareholders Invus […]


Onxeo to present new preclinical data highlighting AsiDNA™’s ability to fight tumor resistance and protect from anticancer treatment toxicity at AACR Annual Meeting 2022

AsiDNA™ proven to overcome resistance to tyrosine kinase inhibitors in lung cancer models AsiDNA™ proven to protect healthy cells when […]


Onxeo’s new preclinical data confirm the relevance of combining AsiDNA™ with PARP inhibitors in treating homologous recombination proficient tumors

These pioneering data were presented at ESMO Targeted Anticancer Therapies Congress 2022   Paris (France), March 9, 2022 – 7:00 […]


Onxeo Announces its Financial Agenda for 2022

Paris (France), January 13, 2022 – 6 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), […]


Onxeo appoints Julien Miara as new interim CEO

Paris (France), January 3rd, 2022 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), […]


New preclinical data confirm the ability of AsiDNA™ to tackle the drug-tolerant persister cells and prevent tumor resistance in several combination treatments

These pioneering data were highlighted at the EACR-AstraZeneca Virtual Conference during two dedicated sessions   Paris (France), December 8, 2021 […]


Onxeo Continues to Strengthen its Board of Directors

Bryan Giraudo, COO & CFO of U.S. biopharmaceutical company Gossamer Bio, joins the Company’s Board as independent member   Paris […]


Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector

Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategy […]


Onxeo Reports its 2021 Half-Yearly Financial Results and Provides an Update on its Activities

Cash position of €24.5 million as of June 30, 2021, providing financial visibility until the end of 2022 and enabling […]


Page 2 of 31